 RedHill Biopharma Ltd NASDAQ: RDHL has announced preliminary results of a new preclinical study for its COVID-19 treatment candidate, opaganib. Related: RedHills Novel Late-Stage Pills Hold Promise Against COVID-19 and its Variants 